Investor Update

Basel, 10 February 2016

Chugai's ALK Inhibitor "Alecensa" Trial Stopped Early for Benefit

Demonstrates Statistically Significant Improvement in PFS in a Japanese Phase III Head to Head Study with Crizotinib

Dear Investor,

Please find attached a press release by Chugai.

Do not hesitate to contact us for any further questions.